Checkpoint inhibitors are increasingly being used in clinical practice; however, these therapies can be associated with adverse events that can affect almost any organ system. This Primer by Ramos-Casals and colleagues summarizes the epidemiology, mechanisms, diagnosis and treatment of these adverse events.
- Manuel Ramos-Casals
- Julie R. Brahmer
- Maria E. Suárez-Almazor
